KAF156, a New Antimalarial, Active and Safe in Small Trial

KAF156 was active against Plasmodium falciparum and Plasmodium vivax in a small phase 2 trial in adults.

Because of increasing resistance of malaria parasites to artemisinin and partner drugs, especially in Southeast Asia, new antimalarials are needed. In a multicenter, open-label, phase 2, manufacturer-sponsored trial, investigators in Thailand and Vietnam assessed the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 (an imidazolopiperazine). This agent has activity against blood stages and the preerythrocytic liver parasite stages. They enrolled adults with uncomplicated Plasmodium vivax or Plasmodium falciparum malaria. Cohorts 1 and 2 (10 patients with P. vivax, 10 with P. falciparum monoinfection) received three daily 400-mg oral doses of KAF156. Cohort 3 (21 participants with P. falciparum monoinfection) received a si…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

KAF156, a New Antimalarial, Active and Safe in Small Trial

Topics

Reviewing Author